Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24625466 | 0.95 | HTT (0.65) | HTTLMNAMAPTTYMPMEN1 | |
| SCHEMBL18392174 | 0.81 | HTT (0.88) | HTTLMNAMAPTTYMPMEN1 | |
| SCHEMBL8901808 | 0.76 | TYMP (0.48) | MAPTTYMPMEN1KMT2AALDH1A1 | |
| SCHEMBL9486338 | 0.75 | LMNA (0.50) | HTTLMNAMAPTTYMPMEN1 | |
| SCHEMBL15655133 | 0.75 | LMNA (0.50) | HTTLMNAMAPTTYMPMEN1 | |
| Diphencyprone SCHEMBL105663 | 0.75 | HTT (1.00) | HTTLMNAMAPTTYMPMEN1 | |
| SCHEMBL142795 | 0.73 | LMNA (0.48) | HTTLMNAMAPTTYMPMEN1 | |
| SCHEMBL24511038 | 0.73 | LMNA (0.48) | HTTLMNAMAPTTYMPMEN1 | |
| SCHEMBL10463403 | 0.72 | ALDH1A1 (0.44) | MAPTMEN1KMT2AALDH1A1CYP2A6 | |
| SCHEMBL10671387 | 0.72 | PTGS2 (0.49) | HTTMAPTMEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10374258-B2 | Cyclobutenedione derivative, nonaqueous electrolytic solution, and lithium ion secondary battery | NEC CORPORATION (JP) | 2019-08-06 | — | — | US | disclosed |
| US-10374258-B2 | Cyclobutenedione derivative, nonaqueous electrolytic solution, and lithium ion secondary battery | NEC CORPORATION (JP) | 2019-08-06 | — | — | US | disclosed |
| US-20170210764-A1 | CYCLOBUTENEDIONE DERIVATIVE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND LITHIUM ION SECONDARY BATTERY | NEC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210764-A1 | CYCLOBUTENEDIONE DERIVATIVE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND LITHIUM ION SECONDARY BATTERY | NEC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210764-A1 | CYCLOBUTENEDIONE DERIVATIVE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND LITHIUM ION SECONDARY BATTERY | NEC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
| US-4986935-A | NONLINEAR OPTICAL DEVICES; COMPOUND HAVING HIGH ACTIVITY FOR SECOND HARMONIC WAVE GENERATION | FUJI XEROX CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4751327-A | Photoconductive imaging members with unsymmetrical squaraine compounds | XEROX CORPORATION (US) | 1988-06-14 | — | — | US | disclosed |
| US-4624904-A | Photoconductive imaging members with unsymmetrical squaraine compounds containing an hydroxyl group | XEROX CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10374258-B2 | Cyclobutenedione derivative, nonaqueous electrolytic solution, and lithium ion secondary battery | HSD17B11, HSD17B7, HSD17B2 | HTT 3964/4885LMNA 2294/4885MAPT 3984/4885 |
| US-20170210764-A1 | CYCLOBUTENEDIONE DERIVATIVE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND LITHIUM ION SECONDARY BATTERY | HSD17B11, HSD17B7, HSD17B2 | HTT 3964/4885LMNA 2294/4885MAPT 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.